NCT06893380 2025-09-15
GENTIS
CHA University
Recruiting
Clinical Trials
11 trialsNCT07098104 2025-08-01
A Benefit Population Atlas of nICT Versus nCT for LAGC
Jiangsu Cancer Institute & Hospital
Completed
NCT06333561 2025-02-06
HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma
Sun Yat-sen University
Recruiting
NCT06760858 2025-01-07
A Prospective Cohort Study on the Treatment of Locally Advanced Gastric Cancer
Southwest Hospital, China
Recruiting
NCT06504875 2024-07-17
Application of PD-1 Monoclonal Antibody in Combination With IL-2 and CapeOX in Organ Preservation Therapy for Ultra-Low Localized Advanced Rectal Cancer
The First Affiliated Hospital with Nanjing Medical University
Not yet recruiting
NCT06448169 2024-06-07
Observational Study on the Sensitivity of Neoadjuvant Immunotherapy in Early Triple-Negative Breast Cancer
Shandong University
Not yet recruiting
NCT04627012 2024-03-06
Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma
Sun Yat-sen University
Completed
NCT05176964 2023-09-25
Chemotherapy and Tislelizumab With Split-course HFRT for Locally Advanced Rectal Cancer
Fujian Medical University Union Hospital
Unknown
NCT06034964 2023-09-13
Tislelizumab Combined With Chemotherapy in First-line Treatment of AGC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Unknown
NCT04996459 2021-08-09
Tislelizumab in the Systematic Treatment of Advanced Hepatocellular Carcinoma
Fudan University
Unknown
NCT04771715 2021-02-25
Regorafenib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Patients With Advanced Colorectal Cancer
Peking Union Medical College Hospital
Unknown